Rapid interrogation of cancer cell of origin through CRISPR editing

Significance Modeling cancer formation requires introduction of relevant oncogenic perturbations into normal cells in a tissue/cell-type–specific manner. Genetically engineered mouse models are powerful but require significant time and cost to generate and maintain. The ability to edit primary epithelial cells ex vivo followed by orthotopic transplantation provides an alternative strategy for cancer modeling but requires efficient gene editing, typically in a multiplex fashion. Here we successfully engineer multigenic perturbations or chromosomal rearrangements in primary prostate organoids through single-step Cas9–sgRNA ribonucleoprotein electroporation. This approach can also address cell-of-origin questions by directly editing and transplanting freshly isolated subpopulations without the intermediate step of organoid culture, providing a rapid complement to traditional lineage tracing approaches. The increasing complexity of different cell types revealed by single-cell analysis of tissues presents challenges in efficiently elucidating their functions. Here we show, using prostate as a model tissue, that primary organoids and freshly isolated epithelial cells can be CRISPR edited ex vivo using Cas9–sgRNA (guide RNA) ribotnucleoprotein complex technology, then orthotopically transferred in vivo into immunocompetent or immunodeficient mice to generate cancer models with phenotypes resembling those seen in traditional genetically engineered mouse models. Large intrachromosomal (∼2 Mb) or multigenic deletions can be engineered efficiently without the need for selection, including in isolated subpopulations to address cell-of-origin questions.

[1]  Luonan Chen,et al.  Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips , 2020, Nature Genetics.

[2]  M. Loda,et al.  A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors , 2020, bioRxiv.

[3]  C. Gersbach,et al.  Immunity to Cas9 as an Obstacle to Persistent Genome Editing. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Amanda R. Kulick,et al.  Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. , 2020, Cancer discovery.

[5]  D. Pe’er,et al.  Regenerative potential of prostate luminal cells revealed by single-cell analysis , 2020, Science.

[6]  Luke Riggan,et al.  CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells. , 2020, Cell reports.

[7]  N. Hosoe,et al.  Chromosome Engineering of Human Colon-Derived Organoids to Develop a Model of Traditional Serrated Adenoma. , 2020, Gastroenterology.

[8]  H. Hieronymus,et al.  Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes , 2019, Molecular Cancer Therapeutics.

[9]  C. Don,et al.  Erratum: Human embryonic stem cell–derived cardiomyocytes restore function in infarcted hearts of non-human primates , 2018, Nature Biotechnology.

[10]  Jack Cuzick,et al.  Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death , 2018, eLife.

[11]  Emma M Schatoff,et al.  Optimized base editors enable efficient editing in cells, organoids and mice , 2018, Nature Biotechnology.

[12]  J. Wilkinson,et al.  A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. , 2018, Cancer cell.

[13]  Hans Clevers,et al.  BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance , 2017, Nature Methods.

[14]  H. Hieronymus,et al.  Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis , 2017, Nature Communications.

[15]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[16]  M. Tomishima,et al.  CRISPR-Cas9–guided oncogenic chromosomal translocations with conditional fusion protein expression in human mesenchymal cells , 2017, Proceedings of the National Academy of Sciences.

[17]  Francisco J. Sánchez-Rivera,et al.  In vivo genome editing and organoid transplantation models of colorectal cancer , 2017, Nature Biotechnology.

[18]  A. Bhardwaj,et al.  In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.

[19]  Jos Jonkers,et al.  Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland , 2016, Genes & development.

[20]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[21]  C. Barbas,et al.  Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells , 2015, Nature Protocols.

[22]  Zhiping Weng,et al.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.

[23]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[24]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[25]  Steven Lin,et al.  Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.

[26]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[27]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[28]  Joana A. Vidigal,et al.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system , 2014, Nature.

[29]  Francisco J. Sánchez-Rivera,et al.  Rapid modeling of cooperating genetic events in cancer through somatic genome editing , 2014, Nature.

[30]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[31]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[32]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[33]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[34]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[35]  Matthew Meyerson,et al.  Targeted genomic rearrangements using CRISPR/Cas technology , 2014, Nature Communications.

[36]  Luke A. Gilbert,et al.  Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2013, Cell.

[37]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[38]  M. Ittmann,et al.  Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. , 2012, Cancer cell.

[39]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[40]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[41]  O. Witte,et al.  Isolation and functional characterization of murine prostate stem cells , 2007, Proceedings of the National Academy of Sciences.

[42]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[43]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[44]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[45]  P. Leder,et al.  Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.

[46]  H. Clevers,et al.  CRISPR-Induced TMPRSS2-ERG Gene Fusions in Mouse Prostate Organoids. , 2017, JSM biotechnology & biomedical engineering.